Market Overview

UPDATE: Goldman Sachs Downgrades United Therapeutics Corporation to Sell; Upside Capped

Related UTHR
New Alzheimer's Trials Could Produce The Most Important Drugs In History
United Therapeutics Corporation Receives Paragraph IV Notice Letter for Tyvaso

Goldman Sachs reduced its rating on United Therapeutics Corporation (NASDAQ: UTHR) from Neutral to Sell while reiterating its price target at $50.

Goldman Sachs noted, "We are downgrading UTHR to Sell from Neutral relative to our Attractive coverage view as we see 4% downside to our $50 12-month price target vs. 12% upside, on average, for our coverage group. The company's base business has been relatively stable (+7% qoq growth in 3Q), and we do not expect its growth trajectory to meaningfully change. Hence, our focus is on terminal value, where a setback on a key pipeline drug (oral Remodulin not approved by FDA) and the ongoing Sandoz patent challenge of UTHR's IV/SQ versions of Remodulin (50% of 2012 revenues) are likely to remain overhangs through 2013."

United Therapeutics Corporation closed at $52.16 on Wednesday.

Latest Ratings for UTHR

Apr 2015Leerink SwannMaintainsMarket Perform
Apr 2015JefferiesMaintainsHold
Apr 2015JP MorganMaintainsNeutral

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (UTHR)

Get Benzinga's Newsletters